# Lusutrombopag Combined With Recombinant Human Thrombopoietin for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Destined to Undergo Elective Invasive Surgery

> **NCT06673498** · PHASE2 · RECRUITING · sponsor: **Anhui Provincial Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Thrombocytopenia

## Interventions

- **DRUG:** Lusutrombopag combined with recombinant human thrombopoietin

## Key facts

- **NCT ID:** NCT06673498
- **Lead sponsor:** Anhui Provincial Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-10
- **Primary completion:** 2025-11-30
- **Final completion:** 2025-11-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06673498

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06673498, "Lusutrombopag Combined With Recombinant Human Thrombopoietin for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Destined to Undergo Elective Invasive Surgery". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06673498. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*